Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo by Oikonomou, E et al.
Newly established tumourigenic primary human colon cancer cell
lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo
E Oikonomou
1, K Kothonidis
2, G Zografos
2, G Nasioulas
3, L Andera
4 and A Pintzas*,1
1Laboratory of Signal Mediated Gene Expression, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Vasileos
Konstantinou Avenue 48, 11635, Athens, Greece;
23rd Department of Surgery, G. Genimatas General Hospital of Athens, Mesogion Avenue 154, 15669,
Athens, Greece;
3Molecular Biology Research Center HYGEIA ‘‘Antonis Papayiannis’’, 4 Erythrou Stavrou and Kifissias Avenue, 15123, Athens, Greece;
4Laboratory of Cell Signaling and Apoptosis, Institute of Molecular Genetics, Czech Academy of Sciences, Videnska 1083, CZ-14220 Prague 4, Czech
Republic
Most data on the therapeutic potential of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as well as resistance to
FAS ligand (FASL) in colorectal cancer have come from in vitro studies using cell lines. To gain a clearer understanding about the
susceptibility of patient tumours to TRAIL and FASL, we derived primary human cancer epithelial cells from colon cancer patients.
Characterisation of primary cultures PAP60 and MIH55 determined their highly proliferating advantage, transforming capability and
tumorigenicity in vitro and in vivo. Although FASL treatment appeared to cause little apoptosis only in the PAP60 primary culture,
increased apoptosis independent of p53 was observed in both primary PAP60 and MIH55 and control cell lines Caco-2, HT29 and
DLD-1 after treatment with SuperKiller TRAIL. Expression analysis of death receptors (DR) in the original parental tumours, the
primary cultures before and after engraftment as well as the mouse xenografts, revealed a significant upregulation of both DR4 and
DR5, which correlated to differences in sensitivity of the cells to TRAIL-induced apoptosis. Treating patient tumour xenograft/SCID
mouse models with Killer TRAIL in vivo suppressed tumour growth. This is the first demonstration of TRAIL-induced apoptosis in
characterised tumorigenic primary human cultures (in vitro) and antitumour activity in xenograft models (in vivo).
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Most sporadic colorectal cancers (CRCs) are thought to develop
from benign adenomas. Progression from normal epithelium
through adenoma to colorectal carcinoma sequence is charac-
terised by accumulated abnormalities to particular genes that
ultimately will invade into the surrounding tissue and metastasise
(Fearon and Vogelstein, 1990). In vitro a well-characterised model
of human colon cancer cell lines exists and reflects the adenoma-
carcinoma progression to facilitate research. On the other hand,
there is paucity of low passage cell lines that will enable close
comparison and the need for implementation with human models
that will closely resemble parental primary human colon cancers is
essential considering the diversity of colon cancers.
Failure in normal apoptotic pathways during carcinogenesis
contributes to the resistance against anticancer drugs or radio-
therapy. Prominent among cell surface molecules capable of
initiating and tightly control apoptosis is the tumour necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L)
and FAS ligand (FASL/Apo1). Tumour necrosis factor-related
apoptosis-inducing ligand is a cytotoxic ligand that induces
apoptosis through ligation and trimerisation of the cell surface
functional death receptor (DR) TRAIL-R1 (DR4) and TRAIL-R2
(DR5), which activates the extrinsic apoptotic pathway. The RNA for
TRAIL is expressed in most tissues of the human body. Although
TRAIL is mostly a membrane-acting protein, small quantities of its
soluble form can also be detected (Mongkolsapaya et al, 1999). The
focus on TRAIL as a potential therapeutic agent became obvious
owing to its differential sensitivity to observe between normal and
cancerous cells (Ashkenazi et al, 1999; Walczak et al, 1999), while its
major advantage lies with its ability to trigger tumour cell apoptosis
in a variety of cancers independent of p53 status (Pitti et al, 1996;
Galligan et al, 2005). Immunohistochemical studies have demon-
strated that the proapoptotic TRAIL receptors DR4 and DR5 are
expressed in normal colon mucosa as well as colorectal adenomas
and carcinomas and their expression was increased in malignant vs
normal cells. In comparison, there is a marked increase in sensitivity
to TRAIL-induced apoptosis associated with progression from
benign to malignant tumour with the assumption that the sensitivity
to TRAIL is acquired early in colorectal tumorigenesis during the
formation of the adenoma (Strater et al, 2002; Koornstra et al, 2003;
Daniels et al, 2005; Hague et al, 2005). However, alterations in cell
surface TRAIL receptor expression may not be the primary reason
for this change.
FAS ligand, a cytokine of the same TNF family is a key molecule
in normal immune function. Engagement of FAS by FASL triggers
a cascade of subcellular events that result in programmed cell
death, or apoptosis (Nagata, 1999). FAS is highly expressed in
normal human colonic epithelial cell and its expression is
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sprogressively decreased during tumour progression from normal
epithelium to adenocarcinoma in about 50% of the cases
(Leithauser et al, 1993; Moller et al, 1994), whereas FASL has
been shown to be upregulated early during colon carcinogenesis
(Bennett et al, 2001). Many colon tumour-derived cell lines exhibit
loss of sensitivity to FAS-mediated apoptosis in vitro (von Reyher
et al, 1998; O’Connell et al, 2000). Reasons proposed for the
decreased FAS sensitivity of colon tumour cell lines include
downregulation of FAS receptor expression (von Reyher et al,
1998), overexpression of Bcl-2 (O’Connell et al, 2000) or FLICE-
inhibitory protein (Ryu et al, 2001) and mutation of p53 (Tamura
et al, 1995). Although this might suggest that during the
transformation process, colon epithelial cells lose sensitivity to
FAS-mediated apoptosis, it is unclear whether FASL upregulated in
colon cancer leads to any increase in apoptosis of the tumour cells
in vivo.
Circumvention of drug resistance via apoptosis induction by
death ligands such as TRAIL and FASL has shown to be effective
in preclinical models. In mouse models, TRAIL demonstrated
remarkable efficacy against tumour xenografts of colon carcinoma
(Ashkenazi et al, 1999; Kelley et al, 2001). Further, combinations
of TRAIL and certain DNA-damaging drugs (Ashkenazi et al,
1999; Morrison et al, 2002) or in combination with chemotherapy
has demonstrated its antitumour effect with prolonged survival
without showing toxicity against normal tissue (Gliniak and Le,
1999; Walczak et al, 1999; Naka et al, 2002; Finnberg et al,
2005).
In contrast, almost no research has been conducted about the
sensitivity of freshly isolated human colon cancer cells to TRAIL
and FASL-induced apoptosis and the limited existing knowledge
is demonstrated only by a handfull of publications. Normal
colonocytes cultured as intact crypts has been previously reported
to be completely resistant to TRAIL-induced apoptosis (Strater
et al, 2002), whereas human colonic epithelia explants were
sensitive to TRAIL-induced apoptosis with or without a chemo-
therapeutic agent (Finnberg et al, 2005). Moreover, an agonistic
anti-FAS mAb enhanced apoptosis in primarily cultured tumour
cells (Yao et al, 2004). Nevertheless, none of the above studies
performed a detailed characterisation of the established colon
cultures and nor explored their molecular characteristics. Mole-
cular analysis and characterisation of newly established colon cell
lines alone has demonstrated that tumorigenicity events are much
more diverse in human colon cancer (Hanahan and Weinberg,
2000). Early attempts to establish human colon cancer cell lines
met little success and only a few low passage cell lines that closely
reflect the properties of the primary tumour cells have been
established and characterised from primary intestinal epithelial
cells (Gibson et al, 1999; Panja, 2000) and gastric cancers (Oh et al,
1999; Yokozaki, 2000). It was therefore necessary to combine all
the above in a single study and investigate the sensitivity of
primary human colon cancer cells to TRAIL and FALS in vitro.
Towards this end, pure epithelia cell lines were established from
two individual patients (PAP60 and MIH55) with CRC and
designated by the pathologists to be at Dukes C (T3N0M0) and
Dukes B (T2N0M0) stage, respectively (Table 1). Of primary
importance in the present study was the characterisation of the
successful primary cultures using methods, which identified
epithelia nature, cell phenotype and growth characteristics. Cell
characterisation was concluded with in vitro and in vivo
tumorigenic assays allowing experiments for primary cell sensi-
tivity to TRAIL- and FASL-induced apoptosis. Sensitivity to
apoptosis was correlated to the RNA expression levels of the
DR4, DR5 and FAS in the established cell lines, an analysis that was
extended to the primary tumours and their respective normal
mucosa as well as their respective mouse xenografts. Tumour
necrosis factor-related apoptosis-inducing ligand receptor analysis
was verified by FACS in the primary cells before and after mouse
engraftment. Finally, Killer TRAIL antitumour activity was
demonstrated in colon cancer patient xenograft/SCID mouse
models in vivo.
MATERIALS AND METHODS
Isolation of primary colon epithelial
Tumour samples and corresponding normal mucosa from two
patients with CRC (Table 1) were obtained from the 3rd
Department of Surgery, G Genimatas General Hospital of Athens
in Greece after approval of the study by the hospital’s ethical
committee and with the written, informed consent from both
patients.
At operation a portion of colon cancer was placed into complete
D-MEM medium (containing 10% foetal bovine serum (FBS),
200Uml
 1 penicillin, 200mgml
 1 streptomycin and 5ml non-
essential amino acids) supplemented with 2.5mgml
 1 ampho-
tericin B, 100mgml
 1 gentamycin and 200mM HEPES (all from
Gibco, BRL, Paisley, UK) and transported to the laboratory
immediately on ice. The freshly resected tissue was cut into small
pieces of o3mm using cross scalpel technique (Cutfix 10
disposable sterile scalpels, Braun) and enzymatically digested with
gentle agitation at 371C for 30–60min with 50mgml
 1 collagenase
type IV (Gibco, BRL), 10mgml
 1 pronase E, 2000Uml
 1 DNAase
and 0.1mM EGTA (all from Sigma, Endorf, Germany). The
dispersed tissue was mixed well by pipetting and filtered through
a 100mm cell strainer (BD Falcon, San Jose, CA, USA) to remove
undigested tissue fragments. Cells were washed with calcium- and
magnesium-free Hank’s Balanced Salt Solution (CMF-HBSS) and
centrifugation at 1000r.p.m. for 2–3min. Colon epithelial cells
were purified using discontinuous (25, 40 and 50%) Percoll
(Arsham, Upsala, Sweden) gradient centrifugation (angle head
rotor) for 20min, at 600 g. Epithelial cells were collected at the
25–40% Percoll interface using a plastic disposable Pasteur pipette
(Copan, Brescia, Italy). Epithelial cells were washed twice with
CMF-HBSS and centrifuged at 1200r.p.m. for 3min. Cell pellet was
resuspended in 20% FBS complete D-MEM medium supplemented
40mgml
 1 gentamycin, 0.1mgml
 1 hydrocortisone and 2mgml
 1
insulin (both from Sigma) and seeded into a T-25 flask pre-coated
with 10mgml
 1 fibronectin. Cell lines were transferred to T-75
flasks and grown to confluence before initial passage. Passage ratio
was dependent on growth rate and cell lines were cryopreserved
before passage 2 and up to passage 10 in complete D-MEM with
20% FBS and 10% dimethyl sulphoxide (Fluka/Sigma-Aldrich,
Bushs, Netherlands) and stored in liquid nitrogen. All experiments
were performed on passage 1–4 cells.
Growth rate of newly established cell lines was determined in
replicate T-25 flasks seeded at 1 10
4cells8ml
 1 complete D-
MEM. Cells were harvested by trypsinisation and counted using a
coulter counter (Coulter Corporation model Z2) after 24, 48, 72
and 144h. Cell numbers were plotted on a log scale vs time and
doubling times were determined during the log phase of growth.
Table 1 Patient information
14–PAP60 15–MIH55
TNM T3N0M0 T2N0M0
Location Sigmoid Rectum
Familial history — —
Histology Middle differentiation Middle differentiation
Chemotherapy — —
Radiotherapy — —
CEA (pre-op) 16.9 1.9
C 19-9 (pre-op) 5.4 4.6
Patient background and diagnosis as determined by the histopathologist.
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sImmunofluorescence
For immunostaining, 5 10
5 cells washed with ice-cold phosphate-
buffered saline (PBS) and fixed with ice-cold methanol:acetone
(4:1) at  201C for 10min. Cells were washed with PBS and
nonspecific antibody binding was blocked with 5% FBS at room
temperature (RT) for 30min. Staining with pan-cytokeratin
(1:300, Sigma, C 2562) or vimentin (1:600, Santa Cruz, CA,
USA, sc-6260) mouse monoclonal antibodies prepared in 1.5% FBS
was performed at RT for 3h, while the secondary antibody Alexa
Fluor 488 goat anti-mouse (1:300, Molecular Probes, Eugene, OR,
USA, A 1001) prepared in 1% FBS was applied to the cells for 1h at
RT. The nuclei were stained with DNA-binding dyes Hoechst no.
33342 (Sigma, B2261) and propidium iodide (Sigma, 81845). Cells
were observed under a fluorescent inverted microscope (Nikon
Eclipse, T-200, Tokyo, Japan).
Mutation analysis
Genomic DNA from the original parental primary tumours (14-
PAP60 and 15-MIH55) and their respective normal mucosa (N14-
PAP60 and N15-MIH55) was prepared by phenol–chloroform
extraction. Each region of exon 5 (codons 126–137) and exon 8
(codons 267–289), considered hot spots for the p53 gene point
mutation in both samples, was amplified by the polymerase chain
reaction (PCR) method for analysis of gene mutation. The
following primers were used: exon 5, sense, 50-TTCCACACCC
CCGCCCGGCA-30, and antisense, 50-CTGGGGACCCTGGGCAA-30;
exon 8, sense 50-AGGACCTGATTTCCTTACTG-30, and antisense,
50-AAGTGAATCTGAGGCATAAC-30. Polymerase chain reaction
was performed with 250ng of genomic DNA and PCR fragments
were purified and sequenced (Biogenomica, Athens, Greece).
Colony formation in soft agar
The anchorage-independent growth on soft agar (Deveney et al,
1996) was used to determine the transformation capability of these
primary colon cancer cells in vitro. A layer (1.5ml) of 0.5% agar in
supplemented D-MEM was first set in each well of a six-well dish
and allowed to equilibrate for 30min at RT. One thousand cells/
well were added to supplement D-MEM containing 0.3% agar,
which was then overlaid onto the first layer of agar. Cells were
incubated at 371C for 10–14 days and medium was replaced every
2 days. Plates were stained with 0.005% crystal violet (Sigma, C
3886)/methanol for 41h and colonies of cells that formed, larger
than 0.5 or 1.2mm, were counted under the inverted light
microscope (Axiovert. 25; Zeiss, D-Jena).
Cell invasion and migration assays
For cell invasion primary colon cells were assayed in 24-well
Transwell inserts (8mm pore membranes, Coster) as described
previously with modifications (Albini et al, 1987). Matrigel
(5mgml
 1) (BD) was diluted to 1.1mgml
 1 in cold serum free
(SF) D-MEM and 100ml of the diluted Matrigel were added into the
upper chambers of the Transwell inserts (4.4mg100ml
 1well) and
incubated for 4–5h at 371C for gelling. Gelled Matrigel was
gently washed with warmed SF D-MEM and 100ml of the cell
suspension in 1% FBS D-MEM was added onto the Matrigel
(10
4cells100ml
 1well
 1). The lower chamber of the Transwell was
filled with 600ml of complete D-MEM containing 5mgml
 1
fibronectin (Sigma), as a chemoattractant. Cell migration along
with a gradient of substratum-bound fibronectin (haptotactic
migration) was assayed in Transwell cell culture chambers as
described previously with modifications (Wickstrom et al, 2004).
For this assay, the lower chamber of the Transwell was filled with
600ml of D-MEM containing 1% FBS and 10mgml
 1 fibronectin, as
a chemoattractant. One hundred microlitres of the cell suspension
in 1% FBS D-MEM were seeded onto the gelatine-coated cell culture
inserts (10
4cells100ml
 1well
 1). The 24-well Transwell was incu-
bated at 371C for 24–36h. The following day, insert chambers were
fixed with absolute methanol for 5min and stained with 0.5% crystal
violet/methanol for 10min. Non-invading cells were moved with a
cotton-tipped swab and only cells on the lower surface of pore filter
were counted under the light microscope ( 200).
Tumorigenicity in SCID mice
To investigate the tumorigenicity of the isolated colon cancer cell
lines, cells were harvested from T-75 flasks (Sarstedt, Nu ¨mbrecht,
Germany) by trypsinisation and washed extensively in PBS. One
million (1 10
6) cells (Caco-2, HT29, PAP60, MIH55) in a total
volume of 100ml PBS were subcutaneously (s.c.) injected (21G
needle) into each flank of a SCID mouse (Charles River
Laboratories Inc., L’Arbresle, Cedex, France). Three female 5-
week-old athymic mice were used per cell line. All animal
experiments were approved by the Animal Ethics Committee of
the Institute of Biological Research and Biotechnology, National
Hellenic Research Foundation and procedures were according to
the guidelines approved by the UKCCCR (Workman et al, 1998).
Tumours were isolated from each condition after 2 weeks of their
appearance and their weight was determined. Removed tumours
had reached an average size of 2cm.
Cytotoxicity and apoptosis assay
For cell viability, cells were seeded into 12-well plates at a density
of 1 10
6cellsml
 1well
 1 and allowed to attach overnight in
complete D-MEM. After overnight equilibration at 371C, medium
was replaced with fresh D-MEM supplemented with varying
concentrations of human recombinant SuperKiller TRAIL (CC-
TRAIL, contains two additional cysteins in the N-terminus behind
the ATG codon and also contains AAs 95–281 of human TRAIL
sequence) and human recombinant rhsSuperFasLigand (FASL)
(200ngml
 1) (ALX-522–020, Alexis). Cells were incubated for 16h
after which cells were washed with PBS and fixed with absolute
methanol for 5min. After methanol was removed, cells were
stained with 0.5% crystal violet/methanol for 10min and subse-
quently washed under tap water. Cells were allowed to dry
overnight after which the remaining crystal violet was extracted
using 30% acetic acid. Absorbance was measured at 595nm and
results presented as percentage of the corresponding control. The
percentages of viable, necrotic and apoptotic cells were assessed by
exposure to the DNA-binding dyes Hoechst no. 33342 (Sigma).
Apoptosis was assessed by immunoblotting for PARP cleavage
(1:1000, Santa Cruz, sc-8007) and caspase-3 activation (1:1000,
Santa Cruz, sc-1225). Apoptotic effects were also assessed in the
presence of Z-VAD-FMK (Alexis) pan-caspase inhibitor.
Reverse transcription–PCR (RT–PCR)
A fresh specimen p0.5cm in any single direction was placed in
5ml RNAlater and transferred to the laboratory at 41C. The
tumour sample (about 100mg) was homogenised in 2ml TRIzol
reagent (Invitrogen, Karlsruhe, Germany) on ice using an electric
tissue grinder (ULTRA-TURRAX, type T-25; Junke and Kunkel).
For cells grown in monolayer, 2ml of Trizol reagent was added
directly to the 3.5cm Petri dish (Greiner). RNA was extracted from
homogenised tissue and lysed cells according to the manufacture.
The dry RNA pellet was dissolved in RNAase-free water and its
concentration was estimated. The extracted total RNA (3mg – cell
lines and tumour samples) was reverse transcribed into cDNA
using the SuperScriptt II Reverse Transcriptase (Invitrogen)
according to the manufacture. For RT–PCR amplification, 5mlo f
cDNA was added to a 50ml reaction containing 6ml reaction buffer
(10 ), 5ml MgCl2, (25mM), 1.5ml deoxynucleotide triphosphate
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sMIH55 (10mM), 3ml of each corresponding 50- and 30- amplimer
(20mM), 0.2ml Taq DNA polymerase (5Uml
 1) (Invitrogen) and
26.3ml autoclaved double-distilled water. Each DNA sample was
amplified using the MJ thermocycler PTC-200. Hot start conditions
were used followed by initial denaturation at 951C (3min) and
final extension at 721C (7min). The reaction for the DR4, DR5 and
GAPDH primers (Drosopoulos et al, 2005) was carried through 28
cycles of 951C (1min, 581C (45s) and 721C (45s)). The reaction for
FAS primers (Rozen and Skaletsky, 2000) was carried through 30
cycles of 951C (1min), 601C (1min) and 721C (1min). Intensity
values were measured using Molecular Dynamics ImageQuant
Software (Amersham Biosciences, Upsala, Sweden). All PCR
products were normalised to GAPDH expression.
FACS analysis
For immunostaining, 5 10
5 cells were preincubated with blocking
buffer (PBS containing 0.2% gelatin, 0.1% sodium azide and
20% FBS) on ice for 10min and then incubated in the staining
buffer (PBS containing 0.2% gelatin and 0.1% sodium azide) with
primary monoclonal antibody DR4 (50mgml
 1, Alexis, HS101)
and DR5 (50mgml
 1, Alexis, HS201) on ice for 30min. After
washing, cells were incubated in the staining buffer containing
phycoerythrin-conjugated goat anti-mouse (GAM-PE) (1:500,
Southern Biotechnology Associates, 1070–09). Cells were then
washed, resuspended in PBS and analysed by flow cytometry. At
least 25000 viable (negative propidium iodide staining) cells were
analysed for each condition.
Mouse xenograft TRAIL study
Human colon cancer cells (DLD-1, PAP60, MIH55; 1 10
6) were
implanted s.c. in the flank of each mouse. Animals bearing
tumours were randomly assigned to six treatment groups (five
mice/group) and treatment initiated after 25 days and when
representative tumours had formed. For the next 5 days, mice
were given daily intravenous (i.v.) injections via the tail vein of
25mgkg
 1day
 1 Killer TRAIL (HisTRAIL, amino acids 95–281)
with low amount of Escherichia coli endotoxins (below 5EU/mg)
purified as described by Plasilova et al (2002). Control groups were
left untreated. After TRAIL treatment, tumour growth and mice
weight were monitored every 5–6 days for 11 days. Tumours were
measured using the Gage digital callipers (Kroeplin GmbH) and
tumour volume was calculated with the formula V¼LD (SD)
2/2,
where V is the tumour volume (mm
3), LD is the longest tumour
diameter and SD is the shortest tumour diameter (Hylander et al,
2005). After day 16, animals were euthanised due to large tumour
size and pieces of tumour p0.5cm in any single direction were
placed in 5ml RNAlater subsequent RT–PCR analysis.
RESULTS
Isolation and establishment of human primary colon
epithelial cells
Percoll gradient-purified colon cancer epithelial cells produced
cultures that contained exclusively epithelial cells only in a limited
number of cases. In most occasions, cultures obtained contained
polygonal-shaped cells and as determined by immunofluorescence
staining with anti-vimentin, they represented fibroblast conta-
mination within the epithelial cells. Cultures obtained from a
successful Percoll gradient purification were shown to be free of
fibroblast contamination by immunofluorescence staining with
anti-vimentin and anti-pan-cytokeratin, where cells reacted
strongly only with anti-pan-cytokeratin giving a negative reaction
for anti-vimentin (Figure 1).
After plating single cells in their respective growth medium, the
cells were observed to attach themselves to the tissue culture vessel
with 16–24h. At this time, the majority of cells were degenerating
and/or dying, and only a few cells remained healthy. Initial
primary cell cultures could be maintained for at least 4 weeks
before their first passage. Early passages of both cell lines were
used in all further experiments presented in this study. Primary
cultures established were of epithelial origin and morphology and
were characterised by patterns of cancer cell growth.
Mutation analysis for p53 indicated point mutations at codon
273 (15-MIH55) and 278 (14-PAP60) in exon 8, suggesting that
mutations in the region of the DNA-binding domain (amino acids
102–292) are correlated with malignancy (Figure 1B, C).
Cellular morphology and growth characteristics of human
primary colon cells
Cellular morphology was analysed under the light microscope for
potential alteration of the normal epithelial phenotype and growth
GER60
14-PAP60
278
CCT-CTT
Pro-Leu
15-MIH55
273
CGT-TGT
Arg-Cys
A
B
C
Figure 1 Establishment of primary human colon cancer epithelial cells by
Percoll gradient centrifugation. (A) Immunofluorescence staining with anti-
vimentin of cultures enriched with both epithelia and fibroblasts and
nuclear staining with propidium iodide. (B, C) Pure epithelial cultures
reacted only with pan-anti-cytokeratin and the nuclei were stained with
Hoechst. The DNA sequence of the p53 gene showed for (B) 14-PAP60 a
point mutation in exon 8 at codon 278 (transition C to T) and for (C) 15-
MIH55 in exon 8 at codon 273 (transition C to T).
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scharacteristics. After plating and while in the first few weeks of cell
proliferation, epithelial cells appeared well rounded and most
single cells begun to spread creating small areas of epithelial
monolayers that formed polarised islets. As cell growth advanced
into the third and fourth week cells showed a tendency to ‘pile-up’
to a different extend on the top of the first layer resulting into
bulks (Figure 2A).
Cell proliferation for each of the primary cell lines was
determined using as controls the known growth rates of
established cell lines (Caco-2 and HT29). Doubling times for
PAP60 and MIH55 ranged from 15 to 18h, respectively, resembling
that of HT29 cells (18h). Specifically, both primary cell lines
PAP60 and MIH55 grew with similar kinetics as the HT29
carcinoma cells. Caco-2 intermediate adenoma cells had the slower
proliferating rate and doubling time of 39h (Figure 2B).
The anchorage-independent growth on soft agar determined the
transformation capability of the primary colon cancer cells in
vitro. Both primary cell lines PAP60 and MIH55 formed tightly
packed and larger colonies as compared with control cell lines
(Caco-2 and HT29) over the period of 2 weeks. Specifically, PAP60
cell line had a significantly increased ability to grow on soft agar
and formed a threefold higher number of colonies as compared
with MIH55 and HT29 cells, whereas the MIH55 cell line formed
a similar number of colonies with the HT29 carcinoma cells
(Table 2). The primary cell lines were subcultured twice before
they were used in this soft agar assay. Both PAP60 and MIH55
exhibited significant transforming capabilities with PAP60 having
the greatest malignant transformation.
In vitro and in vivo tumorigenic characterisation of human
primary colon cells
The tumour cell invasion ability of Matrigel in Transwell cell
culture chamber assay was investigated for the two primary cell
lines PAP60 and MIH55. In particular, PAP60 cells showed better
invasive ability as compared with the MIH55 cells but both
primary cell lines were considerably less invasive when compared
with the control HT29 carcinoma cell line. As the Transwell
chambers include the step of migration for tumour cells to
fibronectin, the haptotactic migration ability of primary cancer
cells was also investigated. In this case, MIH55 cells had an
increased migratory rate compared with the PAP60 cells and
resembled the migration capability of HT29 cells (Table 2).
In a further experiment, the tumorigenic potential of the two
primary cell lines PAP60 and MIH55 was assessed in vivo by their
capacity to grow tumour in mice with multiple immunodeficien-
cies. All mice injected with MIH55 cells developed tumours in 18
days, whereas, eight out of 12 mice developed xenografts in 25 days
after injection with PAP60 cells. Both primary cell lines had similar
tumour formation period that also matched tumour formation
time required by HT29-positive control cells. Of note, tumour
formations were the negative control Caco-2 intermediate
adenoma cells for a period of 3 months (Table 3). It was also
noted that PAP60 allowed for a larger tumour formation compared
with the other cells, whereas the tumours formed by MIH55 were
slightly increased compared with those of HT29 cells. None of the
mice presented a metastasis.
TRAIL- and FASL-induced apoptosis
In order to examine the apoptotic effects of TRAIL and FASL in an
in vitro system of human colorectal carcinogenesis, we subjected
the freshly isolated primary colon cultures PAP60 and MIH55 and
the established colon cells lines Caco-2, HT29 and DLD-1 to TRAIL
and FASL treatment. Tumour necrosis factor-related apoptosis-
inducing ligand (200ngml
 1) and FASL (200ngml
 1) doses
resulted from a dose–response experiment (Figure 3A) and
literature (Fiorucci et al, 2001), respectively. Both primary colon
cultures PAP60 and MIH55 found to be highly sensitive to TRAIL
(200ngml
 1), as they both had significantly reduced viability
within 16h (Figure 3B) by undergoing apoptosis as detected by
Hoechst staining (Figure 4), PARP cleavage and caspase-3
activation (Figure 5). The sensitivity of both primary cell lines to
TRAIL resembled that of DLD-1 cells that are known to be highly
sensitive to TRAIL and was similar to the sensitivity of HT29 cells
that are also sensitive to TRAIL but to a lesser extent. Caco-2
intermediate adenoma cells showed no evidence of apoptosis as
expected. On the contrary, only the PAP60 primary and the
PAP60 MIH55
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Figure 2 (A) Both primary human colon cancer cells (PAP60 and MIH55) exhibit epithelial-like morphology. After forming polarised islets during the first
week of growth (initial growth), (upper panel) they showed a tendency to ‘pile-up’ to a different extend on the top of the first layer, while in advanced
growth (lower panel). (B) Growth rate of primary and established human colon cancer cell lines. Cells were seeded at 1 10
4cell/T-25 flask and counted
every 24h for a period of 5 days.
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ssensitive DLD-1 cells had reduced viability within 16h after FASL
(200ngml
 1) treatment (Figure 3B) by undergoing apoptosis as
detected by Hoechst staining (Figure 4).
Following FASL treatment, partial PARP cleavage was clearly
detected only for the two primary cell lines, while a slight
reduction of the full-length protein (p32) indicated caspase-3
activation (Figure 5). In the presence of the pan-caspase inhibitor
Z-VAD-FMK (25mM), PARP cleavage and caspase-3 activation
were inhibited indicating that caspase-3 activation requires protein
synthesis in the sensitive TRAIL- and FASL-treated cells.
Differential expression of DR in xenografts, respective
primary tumours and derived cultures
The expression levels of the functional TRAIL and FASL receptors
were examined at the RNA level by RT–PCR. Increased levels of
DR4 and DR5 RNA levels were detected in both primary cell lines
PAP60 and MIH55 as compared with the Caco-2, HT29 and DLD-1
cells, whereas highest FAS expression was observed in PAP60 cells
as compared with the MIH55 and control cell lines (Figure 6).
In the original parental tumours of both PAP60 and MIH55,
the DR5 TRAIL receptor was upregulated, while the DR4 was
downregulated as compared with the normal mucosa. When the
primary tumours were transferred in culture, there was a
significant increase in the DR5 receptor expression by 1.8- and
2.2-fold in both PAP60 and MIH55 cells. Same upregulation
pattern was observed for the DR4 receptor, which increased its
expression by 2.3-fold in both primary cultures. Interestingly,
when primary cells were injected into SCID mice, RT–PCR
analysis of the tumour xenografts showed significant down-
regulation of the DR5 that almost matched original expression
levels in the parental tumours. As for the DR4, the cell culture
receptor expression pattern was preserved in the tumour
xenografts. For comparison purposes, same analysis was per-
formed for the control cell lines Caco-2 and HT29, presented no
significant alterations in the expression of DR4 and DR5 receptors
apart from a downregulation in the DR4 receptor expression in the
case of HT29 cells (Figure 6A).
FAS expression analysis showed higher expression in the PAP60
original parental tumour as compared with its normal mucosa,
whereas the opposite expression pattern existed in the MIH55
parental tumour. FAS expression in the primary cultures (PAP60
and MIH55) resembled that of the parental tumours and was
significantly altered in xenograft models only in the case of PAP60
primary culture where it was downregulated by twofold. In
addition, FAS expression was significantly upregulated in mouse
xenografts in Caco-2 intermediate adenoma cells and down-
regulated for in the HT29 carcinoma cells (Figure 6B).
To determine whether the actual expression levels of DR4 and
DR5 receptors were altered on the cell surface before and after
engraftment in SCID mice and how that compares with the RT–
PCR analysis, we performed FACS analysis that confirmed the high
expression levels of DR4 and DR5 before and after engraftment.
Only in case of the PAP60 cells, both receptors were unregulated
after engraftment in SCID mice (Figure 6C).
Activity of killer TRAIL in a SCID mouse xenograft study
In a recent study (Kelley et al, 2001), i.v. administration of a
recombinant human Apo2L/TRAIL (30mgkg
 1) showed signifi-
cant antitumour activity. Data from the present study demonstrate
that tumour suppression was also observed to an extent following
i.v. dosing of Killer TRAIL (25mgkg
 1). Control untreated
tumours increased in tumour size and reduced their body weight
over the period of 16 days, while in treatment groups tumour
increase was significantly longer and body weight had increased
(Figure 7 and Table 4). PAP60 and DLD-1 xenografts showed
intermediate sensitivity to Killer TRAIL in vivo (Figure 7B) and
recorded a decrease in tumour size for 5 days after which tumours
continued to grow (day 16). In case of the MIH55 xenografts, there
was no reduction in tumour size, only decreased rate of tumour
growth was observed. No macroscopical signs of tail cytotoxicity
were observed during treatment administration. RT–PCR analysis
Table 2 In vitro properties
Caco-2 HT29 PAP60 MIH55
Colony formation (CFU) 5.9573.46 138.9730.3 279.8739.5 210.1739
Matrigel transwell invasion 8.372.24 168.3720.7 84.2719.4 64720.7
Transwell fibronectin migration 1871.78 172.3716 145.7717 169711.7
The ability of primary control colon cancer cells to form colonies in 0.3% soft agar and
the invasive and migratory ability through Matrigel-coated membranes and transwell
filter membranes, respectively. The values are mean7STDEV of two individual
experiments performed in duplicates.
Table 3 In vivo properties
Caco-2 HT29 PAP60 MIH55
Tumour formation in days 92.5716.2 21.579.1 2574.2 1870.01
Tumour number 6/9 9/10 8/12 6/6
Tumour mass (g) 0.1970.1 0.3770.007 0.6970.3 0.4270.01
Tumour formation efficiency of primary and control colon cancer cells in SCID mice
after 3 months. Approximately, 10
6 cells were subcutaneously injected into two flanks
of three SCID mice and monitored for tumour formation over time. The values are
means7STDEV of two individual experiments performed in triplicates.
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Figure 3 Response of human colon adenoma-carcinoma cell lines
(Caco-2, HT29 and DLD-1) and primary human colon cancer cells (PAP60
and MIH55) to SuperKiller TRAIL and rhsSuperFasL treatment. (A) A dose
response with TRAIL (25–50–200–350ngml
 1) was performed to
determine the optimal dose. (B) The cells were incubated in the presence
and absence of TRAIL (200ngml
 1) and (FASL 200ngml
 1) for 16h after
which viability was measured. The cytotoxic effects of TRAIL and FASL
treatment were measured with a standard crystal violet staining assay.
Results are present as mean7STDEV of two individual experiments.
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son RNA extracted from mouse xenografts with and without TRAIL
treatment showed an upregulation of DR4 and DR5 only in DLD-1
and PAP60 both of which were sensitive to TRAIL in vivo and had
a reduction in tumour size. During tumour removal, high and
extensive angiogenesis was observed in both control and treatment
groups (Figure 8).
DISCUSSION
Tumour necrosis factor-related apoptosis-inducing ligand has
been shown to exert enhanced apoptotic activity on tumour cells,
while non-tumour cells have been reported to be resistant to
TRAIL-induced death in many systems (Walczak et al, 1999),
whereas FASL kills only sensitive FAS-bearing cells by inducing
apoptosis (O’Connell et al, 1999; Grosch et al, 2001). There have
been only two separate studies where TRAIL- and FASL-induced
apoptosis in primary human colon cancer cells at doses that have
been previously shown to be sensitive in several colon cancer cell
lines in vitro (Yao et al, 2004; Finnberg et al, 2005). However, none
of the above studies combined extensive characterisation of the
primary cells. So far, the use of continuous growing tumour cell
lines resulted in many data on the triggering of apoptosis by
several chemotherapeutics, including TRAIL and FASL, but little is
known about this process in primary human epithelia. In contrast
to the continuous growing colon cell lines, human colonic cancer
tissue exhibits a number of different cell types at various stages of
differentiation and thus may differ in proliferation rates. Since the
differences between cell lines and primary cultures are not limited
to the growth rate, extensive characterisation of the primary
epithelial is essential. This is the first study where characterised
low passage tumorigenic primary human colon cancer cell lines
PAP60 and MIH55 have been analysed in vitro (cell culture) and in
vivo (SCID mice) for their sensitivity to TRAIL- and FASL-induced
apoptosis administered as single agents. Both primary cell lines
were highly sensitive to TRAIL-induced apoptosis (in vivo and in
vitro) in contrast to the moderate sensitivity exhibited upon FASL
treatment (in vitro) only by the PAP60 cells. Hereby, TRAIL alone
induced apoptosis in the primary cultures when other studies
demonstrated that combination and/or pretreatment of TRAIL
with other anticancer agents was required to increase ability to
induce apoptosis in both primary and established cell lines
(Finnberg et al, 2005). Following TRAIL treatment of primary
cultures, typical apoptotic morphology indicated cell death by
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Figure 4 (A) Nuclear staining of primary colon cells PAP60 and MIH55 with Hoechst after 6-h treatment with TRAIL (200ngml
 1) (upper panel) and
FASL (200ngml
 1) (lower panel). (B) Five random fields were checked for apoptotic or necrotic nuclei and indicated here by arrows.
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Figure 5 (A) PARP degradation and (B) caspase-3 activation of primary
(PAP60 and MIH55) and control (DLD1) colon cells induced by TRAIL and
FASL. Cells were treated for 60–120min with TRAIL (200ngml
 1) and
FASL (200ngml
 1) in the presence (1h pretreatment) and absence of
a pan-caspase inhibitor Z-VAD-FMK (25mM). Whole-cell lysates were
checked with WB for characteristic PARP cleavage (120min) and caspase-3
activation (60min).
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sapoptosis that was verified by PARP cleavage and caspase-3
activation. The apoptotic effect of TRAIL was independent of the
p53 mutations, as both primary cell lines had mutated p53 at sites
associated with the DNA-binding activity (Galligan et al, 2005).
Tumour necrosis factor-related apoptosis-inducing ligand-induced
apoptosis has been shown to be of different intensity and
irrespective to the TRAIL receptor status in the different human
colon cell lines. This heterogeneity in cell sensitivity is attributed
to different factors such as the presence of oncogenes (Drosopoulos
et al, 2005) or mutated caspases implicated in the downstream
signalling (Kim et al, 2003). Similarly, FASL is also selective to
the different colon cancer but to a greater extend. Cells that
abundantly express FAS are nonetheless resistant to FASL-
mediated apoptosis. This in turn, has been attributed to
intracellular defects in FAS signalling and upregulation of the
FASL when a downregulation of the FAS occurs (Houston et al,
2003). In the present study, only one of the two established
primary cultures, MIH55, was modestly sensitive to FASL-induced
apoptosis as confirmed by partial PARP cleavage and caspase-3
activation. Even though both cell lines were highly tumorigenic,
PAP60 did present a better transforming capability and elevated
proliferation rate but was less able to migrate through Matrigel-
coated filters and form tumours in SCID mice compared with the
MIH55 cell line. Regardless, PAP60 expressed higher levels of FAS
that correlated to its sensitivity to FASL. According to previous
reports, FAS expression was progressively decreased during
tumour progression from normal epithelium to adenocarcinoma
(Leithauser et al, 1993; Moller et al, 1994), which leads to conclude
that other factors rather than receptor expression alone influence
cell sensitisation.
Prevalent expression of DR4, 5 and FAS in both human colon
cancers was confirmed by RT–PCR analysis. The analysis initiated
from the original parental tumours 14 (PAP60) and 15 (MIH55)
and their corresponding normal mucosa N14 (PAP60) and N15
+ + +
• •• •• •
• • • • • •
+ +
0
0.5
1
1.5
2
C
a
c
o
-
2
H
T
2
9
D
L
D
-
1
P
A
P
6
0
M
I
H
5
5
C
a
c
o
-
2
 
x
e
n
o
g
r
a
f
t
H
T
2
9
 
x
e
n
o
g
r
a
f
t
P
A
P
6
0
 
x
e
n
o
g
r
a
f
t
M
I
H
5
5
 
x
e
n
o
g
r
a
f
t
N
1
4
-
P
A
P
6
0
1
5
-
M
I
H
5
5
1
4
-
P
A
P
6
0
N
1
5
-
M
I
H
5
5
C
a
c
o
-
2
H
T
2
9
D
L
D
-
1
P
A
P
6
0
M
I
H
5
5
C
a
c
o
-
2
 
x
e
n
o
g
r
a
f
t
H
T
2
9
-
x
e
n
o
g
r
a
f
t
P
A
P
6
0
-
x
e
n
o
g
r
a
f
t
M
I
H
5
5
-
x
e
n
o
g
r
a
f
t
N
1
4
-
P
A
P
6
0
1
5
-
M
I
H
5
5
1
4
-
P
A
P
6
0
N
1
5
-
M
I
H
5
5
DR4
DR5
R
e
l
a
t
i
v
e
 
R
N
A
 
l
e
v
e
l
s
0
0.5
1
1.5
2
R
e
l
a
t
i
v
e
 
R
N
A
 
l
e
v
e
l
s
DR4
DR5
GAPDH
***
***
+++
+++
• •• • • •
421 bp
517 bp
133 bp
244 bp
133 bp
FASR
GAPDH
FASR
***
**
***
+++
• • • •• •
PAP60 DR4 
PAP60 DR4 
xenograft
PAP60 DR5
PAP60 DR5 
xenograft
MIH55 DR4 
MIH55 DR4 
xenograft
MIH55 DR5
MIH55 DR5 
xenograft
PAP60 MIH55
PAP60 PAP60 xenograft
GAM-PE 14.40 14.35
TRAIL-R1 (DR4) 190.93 314.73
TRAIL-R2 (DR5) 83.65 95.51
MIH55 MIH55 xenograft
GAM-PE 18.56 16.12
TRAIL-R1 (DR4) 262.01 279.85
TRAIL-R2 (DR5) 88.18 83.17
Geometric mean Geometric mean
300
240
180
120
60
0
100 101 102 103 104
FL2-H
300
240
180
120
60
0
100 101 102 103 104
FL2-H
A B
C
Figure 6 Relative RNA levels of (A) DR4, DR5 and (B) FAS in primary PAP60 and MIH55 and control Caco-2, DLD-1 and HT29 human colon cancer
cell lines was performed by RT–PCR analysis. The analysis was expanded to the cell xenografts as well as the original parental primary tumours (14-PAP60,
15-MIH55) and their respective normal mucosa (N14-PAP60, N15-MIH55). The analysis was performed in triplicates and the mean7STDEV is shown.
Columns, relative RNA level normalised to GAPDH.
**Po0.01,
***Po0.001 vs respective control cell lines in culture;
þþPo0.01;
þþþPo0.001 vs
respective control cell line in culture; Po0.01; Po0.001 vs primary parental tumour. Student’s two-tailed t-test was used. (C) Flow cytometry of DR4 and
DR5 receptor expression on the cell surface in primary colon cancer cell lines PAP60 and HIM55 before and after engraftment in SCID mice. The data are
presented as the log peak fluorescence intensity of untreated cells. The numbers in the first row represent the background signal when only the secondary
antibody GAM-PE is used.
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s(MIH55) and carried through the tumour-derived primary cultures
PAP60 and MIH55. In both cases, DR5 was upregulated compared
with the normal mucosa, whereas the DR4 was downregulated. In
the primary cultures, both TRAIL receptors were upregulated,
which translated to the increased sensitivity to TRAIL-induced
apoptosis. When the primary cells were injected into athymic SCID
mice, expression of DR4 and DR5 was significantly downregulated
to levels comparable with those initially observed in the original
parental tumours. Subculturing or transfer of cells away from host
environment will induce them to become transformed and
differentiated. This might explain differential expression of the
receptors through out the different experimental models. The
possibility that DR5 upregulation is a result of stress may be part
of the natural homoeostasis process and the present finding could
lead to better understanding of the large diversity of colon cancer
tumour occurring in patients and their different response once
removed from their host environment. Tumour-derived cells in
culture may compromise some of their parental characteristics;
therefore, it is important that experiments are performed during
early passages. Even if DR5 upregulation in culture is a result of
stress, expression levels in the original parental tumours cover for
the sensitivity of the cells to TRAIL treatment.
On the contrary, FAS expression was upregulated in tumour 14
(PAP60) compared with the receptor downregulation observed
in tumour 15 (MIH55), which also correlated to the increased
sensitivity of PAP60 tumour-derived cells to FASL. Nevertheless,
FAS expression pattern observed for both parental tumours was
not altered in corresponding primary cultures, whereas only
PAP60 downregulated FASR in mice xenografts. The p53 muta-
tions detected in both primary cell lines might play a role, as
previously suggested (Tamura et al, 1995), in the downregulation
of the FAS observed in 15-MIH55 as compared with the normal
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Figure 7 Effect of TRAIL on tumour formation. SCID mice (n¼5/group) were injected s.c. with 10
6 (A) DLD-1, (B) PAP60 and (C) MIH55 cells.
Twenty-five days later, established xenografts were given Killer TRAIL (25mgkg
 1d
 1) as an i.v. bolus for 5 consecutive days or left untreated. All
experiments were in compliance with the UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia. After TRAIL treatment, tumours were
measured on every fifth or sixth day for a period of 11 days. Arrows indicate the 5-day period of TRAIL treatment. Results shown are group mean7STDEV.
After day 16, animals were euthanised due to large tumour size.
Table 4 Group average tumour weight
DLD-1 PAP60 MIH55
Untreated TRAIL 200mgkg
 1day
 1 Untreated TRAIL 200mgkg
 1day
 1 Untreated TRAIL 200mgkg
 1day
 1
Day 0 16.7571.7 12.7571.7 16.2071.1 15.4072.0 18.2572.1 15.7571.5
Day 8 14.2572.1 13.2571.2 15.0071.2 15.1071.9 16.7573.0 16.1070.9
Day 11 14.2572.1 13.7572.1 14.0071.2 15.5071.8 15.5072.1 16.7571.3
Day 14 14.7571.3 12.7571.8 13.8070.8 15.4071.9 14.7572.1 15.7571.8
Data are group average tumour volumes7STDEV (n¼5 mice/group).
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smucosa and the decreased sensitivity of both primary cell lines
(PAP60 and MIH55) to FASL treatment. Even though a number of
studies tested TRAIL in vivo for its ability to induce apoptosis
in tumour xenografts, none ever reported on the DR status or
alterations in the cell lines before and while in SCID mice (Gliniak
and Le, 1999; Walczak et al, 1999; Kelley et al, 2001; Naka et al,
2002; Finnberg et al, 2005; Hylander et al, 2005). FACS analysis
confirmed the high expression levels of DR4 and DR5 in the
primary cultures before and after engraftment in SCID mice.
Further evidence is also provided about the functional significance
of KILLER/DR5 by demonstrating that DR5 is the most
differentially expressed DR between the different conditions.
KILLER/DR5-mediated tumour suppression and contribution to
drug-induced apoptosis importantly identify KILLER/DR5 as a
promising therapeutic target for the management of CRCs (Wang
and El-Deiry, 2004).
Taken together, the present study demonstrates the antitumour
activity of TRAIL in a cytotoxicity (SuperKiller TRAIL) assay and
xenograft models (Killer TRAIL) of primary CRC after i.v.
administration, which was correlated to DR upregulation and
provides estimates of the disposition of TRAIL in humans. Other
apoptosis-inducing members of the TNF family carried great
promise as anticancer agents at the cost of severe toxicities toward
normal tissues have hampered their use as cancer therapeutics.
Administration of agonistic anti-FAS antibodies or recombinant
human FASL to rodents results in lethal liver damage (Ogasawara
et al, 1993; Tanaka et al, 1997). The absence of macroscopic
toxicity using low TRAIL concentrations (25mgkg
 1) is encoura-
ging for further bioactivity and pharmacokinetic studies to
implement present findings. Combination of TRAIL with che-
motherapy managed to reduce cytotoxicity (Naka et al, 2002;
Finnberg et al, 2005). Therefore, introducing in the in vivo studies
promising synergistic to TRAIL agents such as Quercetin that
have been proved efficient in vitro in our lab (Psahoulia et al,
unpublished data) may lower cytotoxicity by reducing even more
TRAIL concentrations leading to more efficient targeted therapies.
In the early part of these studies, it proved difficult to obtain a
cell isolation with good viability that was enriched with pure
epithelial cell. The success in culturing human colon epithelial cells
is likely due to several factors like the clinical staging of the
tumour. Primary cancers that had demonstrated metastasis either
to regional nodes (Dukes Stage C) or distant sites (Dukes Stage D)
or originated from the right side of the colon present better
chances of survival and successful culture (McBain et al, 1984).
Regardless protocol adaptations, the success rate remained low
where only two out of five (40%) colon cancer biopsies survived
to be of pure epithelial origin. The procedure involved tissue
digestion for not more that 30min with an enzyme cocktail that
contained collagenase as a primary enzyme, pronase E to intensify
the action of collagenase, as alone in high concentration was fatal
for the cells and DNAse. Collagenase alone and longer incubation
periods proved unsuccessful. The presence of EGTA helps to
reduce rapidly the local (Ca2þ)i providing cells with damaged cell
membranes to better attachment capability. Percoll gradient
purification was used for epithelial isolation and was far more
successful than using culture medium were L-Valine was
substituted for D-Valine in the presence of which only cancer
cells can continue grow. Isolated cancer epithelial was seeded on
fibronectin-coated vessels as the isolation procedure heavily
damages the cell membrane reducing the attachment ability of
the cells down to 6%. Successful long-term cultures of primary
cancer colonic epithelial will contribute to better understanding of
the function of human disease and CRC in specific. The established
primary cell lines provided an essential experimental model for
testing TRAIL- and FASL-induced apoptosis and receptor expres-
sion reflecting the great diversity that exits in colon cancer.
Future therapeutics
For colon carcinomas, the combination of subthreshold doses of
recombinant TRAIL with existing chemotherapeutic agents
resulted in a substantial positive interaction, completely eliminat-
ing the tumours in some animals. These results look encouraging,
although in the absence of human clinical testing, there is no
certainty that the positive results achieved in animal models will
translate to the complexities of the true human disease. Towards
this end, primary colon cultures of derived cells presented in this
study or explants investigated elsewhere may provide findings that
resemble the human nature.
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Figure 8 Relative RNA levels of (A) DR4, DR5 and (B) FAS in primary
PAP60 and MIH55 and control DLD-1 human colon cancer cells was
performed by RT–PCR analysis on established xenografts with and without
TRAIL (15mg/kg/d) treatment. The analysis was performed in quad-
ruplicates and the mean7STDEV is shown. Columns, relative RNA level
normalised to GAPDH. *Po0.01, ***Po0.001 vs untreated. Student’s
two-tailed t-test was used.
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